Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are methods of treating cancer in a patient comprising administering a total daily dose of 240 mg sotorasib to the patient, wherein the cancer is a KRAS G12C mutated cancer. Also provided herein are methods of treating KRAS G12C mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: A method includes obtaining behavioral source code defining logic to be performed using at least one logic device, hardware information associated with the at least one logic device, and constraints identifying user requirements associated with the at least one logic device. The method also includes generating a design for the at least one logic device using the behavioral source code, the hardware information, and the constraints. The design enables the at least one logic device to execute the logic while satisfying the user requirements. The design is generated using a machine learning/artificial intelligence (ML/AI) algorithm that iteratively modifies potential designs to meet the user requirements.

Abstract: Techniques are described for domain adaptation of image processing models using post-processing model correction According to an embodiment, a method comprises training, by a system operatively coupled to a processor, a post-processing model to correct an image-based inference output of a source image processing model that results from application of the source image processing model to a target image from a target domain that differs from a source domain, wherein the source image processing model was trained on source images from the source domain. In one or more implementations, the source imaging processing model comprises an organ segmentation model and the post-processing model can comprise a shape-autoencoder. The method further comprises applying, by the system, the source image processing model and the post-processing model to target images from the target domain to generate optimized image-based inference outputs for the target images.

Abstract: Systems and techniques for generating and/or employing a computed tomography (CT) medical imaging fracture model are presented. In one example, a system employs a first convolutional neural network associated with vertebrae segmentation to generate learned vertebrae segmentation data regarding a spine anatomical region related to a CT image. The system also employs a second convolutional neural network associated with fracture segmentation to generate, based on the learned vertebrae segmentation data, learned fracture segmentation data regarding the spine anatomical region. Furthermore, the system detects presence or absence of a medical fracture condition in the CT image based on the learned vertebrae segmentation data and the learned fracture segmentation data.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: A system and method for estimating vascular flow using CT imaging include a computer readable storage medium having stored thereon a computer program comprising instructions, which, when executed by a computer, cause the computer to acquire a first set of data comprising anatomical information of an imaging subject, the anatomical information comprises information of at least one vessel. The instructions further cause the computer to process the anatomical information to generate an image volume comprising the at least one vessel, generate hemodynamic information based on the image volume, and acquire a second set of data of the imaging subject. The computer is also caused to generate an image comprising the hemodynamic information in combination with a visualization based on the second set of data.

Abstract: A system and method for estimating vascular flow using CT imaging include a computer readable storage medium having stored thereon a computer program comprising instructions, which, when executed by a computer, cause the computer to acquire a first set of data comprising anatomical information of an imaging subject, the anatomical information comprises information of at least one vessel. The instructions further cause the computer to process the anatomical information to generate an image volume comprising the at least one vessel, generate hemodynamic information based on the image volume, and acquire a second set of data of the imaging subject. The computer is also caused to generate an image comprising the hemodynamic information in combination with a visualization based on the second set of data.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features interferon-free therapies for treating Hepatitis C Virus (HCV) genotypes 1b, 2, 3 or 4. In one aspect, the therapies comprises administering Compound 1 (Paritaprevir), Ritonavir, and Compound 2 (Ombitasvir) to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include the administration of any interferon, and the therapies last from 8 to 12 weeks. Preferably, the therapies do not include the administration of any ribavirin.

Abstract: This application features dose adjustment for drugs co-administered with glecaprevir and pibrentasvir.

Abstract: The present invention generally features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16, 12 or 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. Further, additional compounds such as sofosbuvir, or its pharmaceutically acceptable salt may be used for retreatment of HCV patients who have failed glecaprevir and pibrentasvir combination therapy.

Abstract: A method is provided for simulating a program executable by a processor and a circuit design configured to communicate with the processor. A processor on a programmable IC is configured to execute the program. Programmable resources on the programmable IC are configured to implement a plurality of interface circuits. Each of the interface circuits is configured to communicate data between the processor and a simulation environment using a respective communication protocol. The interface circuits that uses a communication protocol used by the circuit design is enabled and other ones of the interface circuits are disabled. The circuit design is simulated in a simulation environment coupled to the programmable IC. During the simulating, the program is executed on the processor and data is communicated between the processor and the computing platform using the determined one of the plurality of interface circuits.

Abstract: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half-life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: A method is provided including determining at least one range of phases of a cardiac cycle from which to select a selected phase based on at least one of patient demographic information, patient physiological information, or a general physiological model. The method also includes generating corresponding intermediate images for each of the phases of the at least one range of phases. Further, the method includes selecting the selected phase based on at least one image quality (IQ) metric of the intermediate images. Also, the method includes generating an image for diagnostic use using imaging information from the selected phase.

Abstract: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.

Abstract: Embodiments are adapted for acquiring projection data from a computed tomography imaging system to form motion-corrected images of cyclically moving imaging subjects. Embodiments determine a start time and time duration of a data record with sufficient data for forming a motion-corrected image from the data record, without screening data records or images for motion artifacts. Some embodiments acquire data asynchronously with respect to the cyclical motion of the imaging subject, without using a signal such as an EKG to select a period of low subject motion for imaging. Other embodiments use a pulse signal synchronized to the imaging subject's motions to reduce an amount of data presented for image reconstruction, or to target a specific phase of the imaging subject's cyclical motion.